Atomo Diagnostics

Each year in the U.S., 2.8 million antibiotic-resistant illnesses and 35,000 deaths are linked to inappropriate prescribing. FebriDx® on the Pascal platform changes this. In just minutes, clinicians can determine if an acute respiratory infection is bacterial—supporting rapid, evidence-based care and reducing the overuse of antibiotics. Deliver better outcomes for patients and help protect antibiotics for the future.

Antibiotic resistance is one of the UK’s most pressing health threats, yet antibiotics are prescribed unnecessarily in up to 50% of acute respiratory infections. With FebriDx® on the Pascal platform, clinicians get an accurate bacterial vs viral result in minutes, right at the point of care. The result? Reduced misuse of antibiotics, improved stewardship, and more confident treatment decisions during the patient visit.

The clip-in Florey cassette, built on the Pascal cassette’s functionality and IP, improves ease of use and increases accuracy in blood and buffer delivery—reducing errors by over 90%. With no changes to your cassette or pouch, Florey minimises regulatory burden and avoids manufacturing disruption. Head to our website to learn more and enquire about collaboration opportunities.

The clip-in Florey cassette, built on the Pascal cassette’s functionality and IP, improves ease of use and increases accuracy in blood and buffer delivery—reducing errors by over 90%. With no changes to your cassette or pouch, Florey minimizes regulatory burden and avoids manufacturing disruption. Head to our website to learn more and enquire about collaboration opportunities.

"These solutions reduce error rates, improve care and have significant commercial potential in both the developing world and in developed healthcare markets." - Dr. Curt LaBelle Managing Partner, Global Health Investment Fund Partner with us for an efficient, low-risk pathway from product development to commercialization.

"These solutions reduce error rates, improve care and have significant commercial potential in both the developing world and in developed healthcare markets." - Dr. Curt LaBelle Managing Partner, Global Health Investment Fund Partner with us for an efficient, low-risk pathway from product development to commercialisation.